Clinical Trials Browser

Phase 2 × Neoplasms × fludarabine × Clear all

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05993299 2026-03-11

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Tumor-Agnostic

Neoplasms

NCT03967223 2026-02-25

IGNYTE-ESO

Phase 2 Active not recruiting

103 enrolled

Sarcoma

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06703346 2026-02-25

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

87 enrolled

Tumor-Agnostic

Neoplasms

NCT06001385 2026-02-05

OPTIMIZE

Phase 2 Active not recruiting

313 enrolled

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2 Withdrawn

Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05972720 2025-05-15

FIRCE-1

Phase 2 Terminated

101 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2 Completed

35 enrolled 14 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02992743 2023-04-11

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Phase 2 Completed

23 enrolled 25 charts

Sarcoma

Neoplasms, Liposarcoma, Myxoid

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2 Withdrawn

Sarcoma

Neoplasms, Sarcoma, Synovial

NCT01271907 2017-08-01

Drosophila-generated CTL

Phase 2 Terminated

3 enrolled 8 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT00582933 2016-02-01

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

Phase 2 Completed

96 enrolled 5 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms

Clinical Trials

ACCESS

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

IGNYTE-ESO

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

OPTIMIZE

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

FIRCE-1

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Drosophila-generated CTL

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor